Go offline with the Player FM app!
First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia
Manage episode 448946452 series 2592278
In this week's episode we’ll learn more about the ASCEND study, which investigated first-line asciminib in chronic phase chronic myeloid leukemia; a new risk score for myeloid neoplasm transformation in patients with clonal cytopenia of undetermined significance; and use of RHD genotyped D-positive blood transfusions in patients with sickle cell and unexpected anti-D antibodies.
Featured Articles
- Asciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia - Results from the ASCEND Study
- Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence
- Genotyped RhD+ red cells for D-positive patients with sickle cell disease with conventional RHD and unexpected anti-D
315 episodes
Manage episode 448946452 series 2592278
In this week's episode we’ll learn more about the ASCEND study, which investigated first-line asciminib in chronic phase chronic myeloid leukemia; a new risk score for myeloid neoplasm transformation in patients with clonal cytopenia of undetermined significance; and use of RHD genotyped D-positive blood transfusions in patients with sickle cell and unexpected anti-D antibodies.
Featured Articles
- Asciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia - Results from the ASCEND Study
- Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence
- Genotyped RhD+ red cells for D-positive patients with sickle cell disease with conventional RHD and unexpected anti-D
315 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.